Developer docs
API playgroundTry for free, no card

Search company profiles

BioSpyder Technologies

Full company profile

uuid0006zf1

Namestring
BioSpyder Technologies
Legal namestring
BioSpyder, Inc.
Websiteurl
biospyder.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

BioSpyder Technologies is a Carlsbad, California-based life sciences tools company founded in December 2011 by Joel McComb (CEO), Joanne Yeakley (VP R&D), and Bruce Seligmann (CSO) that develops and commercializes TempO-Seq (Templated Oligo-Sequencing), a proprietary targeted sequencing platform for gene expression profiling. The platform uses template-dependent detector oligo ligation chemistry that interrogates RNA directly without requiring RNA extraction, cDNA conversion, or pre-amplification, enabling analysis of cell lysates, FFPE tissue, frozen tissue, dried blood spots, and miRNA inputs on standard PCR instruments or microplate incubators. The platform can multiplex up to 6,144 samples per sequencing run with 99% single-base mismatch specificity and supports panels covering human, mouse, rat, zebrafish, and EcoTox species.

The company's product portfolio includes the core TempO-Seq assay, pre-designed whole-transcriptome and S1500+ surrogate panels, TempO-LINC (single-cell, launched 2025), TempO-Seq miRNA (2,112 targets), TempO-Seq Dried Blood Spot, TempO-SPan (pathogen detection including SARS-CoV-2/Influenza/RSV), and the upcoming TempO-SNP genotyping assay. BioSpyder also operates the TempO-Seq Portal cloud analysis module and offers managed bioinformatics services including probe design, differential expression analysis, and machine learning classification. Revenue is generated through quote-based kit and panel sales, full-service sample processing projects with 4–6 week turnaround, and bioinformatics consulting.

BioSpyder targets four primary customer segments: pharmaceutical and biotech companies conducting early compound screening and drug development safety assessment, toxicology and environmental science researchers (including regulatory chemical safety), oncology research groups pursuing biomarker discovery, and academic/government genomics labs. Commercial distribution is direct in the USA and through regional distributors covering Scotland, Spain, South Korea, Japan, Hong Kong, Thailand, Singapore, and Malaysia. The company is privately held by its three co-founders with no disclosed institutional investors; R&D has been substantially supported by competitive NIH grants from NHGRI, NIEHS, NCATS, NCI, and NIFA/USDA, and its technology is protected by a broad international patent estate.

Short descriptiontext

BioSpyder Technologies develops and commercializes TempO-Seq, a proprietary targeted sequencing platform for high-throughput gene expression profiling that bypasses RNA extraction. The Carlsbad, California company sells assay kits, panels, and full-service sequencing to pharmaceutical, toxicology, oncology, and academic researchers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCarlsbad, United States
HQ citystring
Carlsbad
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene expression profiling, targeted sequencing assays, single-cell transcriptomics, molecular diagnostics tools, bioinformatics analysis services
Industry5 codes
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code5 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Software Publishers5132
SIC code4 codes
  • Laboratory Analytical Instruments3826
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Prepackaged Software7372
Product category
Genomics Assay Products
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1TempO-Seq Kits and Panels
TypeOne Time License
Description

Sale of assay kits including whole transcriptome panels, S1500+ surrogate panels, and custom panels for human, mouse, rat, zebrafish, and EcoTox species. Customers can purchase panels directly and run assays in their own labs.

biospyder.com
2Service Projects
TypeProfessional Services
Description

BioSpyder processes customer samples using TempO-Seq and TempO-LINC platforms. Service projects typically have 4-6 week turnaround. Deliverables include FASTQ files, count tables, and service reports.

biospyder.com
3Bioinformatics Services
TypeProfessional Services
Description

Additional data analysis support including probe design, exploratory data analysis, differential gene expression analysis, machine learning classification, pathway analysis, and single-cell analysis.

biospyder.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure, Operations
Pricing details1 tier
1Kits and panels - quote-based pricing
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Panels available for human, mouse, rat, zebrafish whole transcriptome and S1500+ surrogate assays. Custom panel development offered. No public pricing - requires contact for quote.

biospyder.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1TempO-Seq
Description

Proprietary targeted sequencing platform for gene expression profiling using templated oligo detection chemistry, capable of analyzing hundreds to thousands of genes in high throughput.

biospyder.com
+4 more records
Core offering1 text field

BioSpyder develops and sells the TempO-Seq (Templated Oligo-Sequencing) targeted sequencing platform for gene expression profiling, offering assay kits and pre-designed panels (human, mouse, rat, zebrafish, EcoTox species) that customers run in their own labs, as well as fee-for-service projects (4–8 week turnaround) where BioSpyder processes customer samples and delivers FASTQ files, count tables, and analysis reports. The proprietary chemistry eliminates RNA extraction, cDNA conversion, and pre-amplification, supports multiplexing of up to 6,144 samples per run, and is complemented by the cloud-based TempO-Seq Portal and managed bioinformatics services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Up to 6,144 samples multiplexed in single sequencing run
+4 more records
Product overview1 text field

BioSpyder Technologies offers the TempO-Seq (Templated Oligo-Sequencing) platform as its core product — a targeted sequencing system for gene expression profiling that avoids RNA extraction, cDNA conversion, or pre-amplification through proprietary detector oligo ligation chemistry. The platform comprises multiple specialized sub-products: TempO-Seq (core targeted sequencing assay accepting diverse inputs), TempO-Seq Dried Blood Spot (blood-based transcriptomics), TempO-Seq miRNA (microRNA profiling), TempO-LINC (single-cell expression profiling service), TempO-SNP (SNP detection, upcoming), and TempO-SPan (pathogen/respiratory virus detection). These are complemented by the TempO-Seq Portal cloud analysis module and managed Bioinformatics Services for custom probe design, differential expression, machine learning classification, pathway analysis, and single-cell analysis. Pre-designed panels cover human, mouse, rat, zebrafish transcriptomes and EcoTox species. The platform is validated across applications in toxicology, oncology, pharma, computational biology, and agriculture.

Product and service9 records
1TempO-Seq
CategoryTargeted Sequencing Assay
Description

TempO-Seq (Templated Oligo-Sequencing) is a targeted sequencing assay for gene expression profiling that monitors hundreds to thousands of genes in high throughput without RNA extraction, cDNA conversion, or pre-amplification. It uses proprietary detector oligo ligation chemistry, accepts diverse input types (cell lysates, FFPE tissue, frozen tissue, dried blood spots, miRNA), and enables pooling of up to 6,144 samples per run on standard PCR instruments or microplate incubators.

2TempO-Seq Dried Blood Spot
CategoryTargeted Sequencing Assay
Description

A TempO-Seq variant that enables whole transcriptome profiling from dried whole blood or buffy coat samples on filter paper, collected by finger prick or venipuncture. Uses modified chemistry that maintains RNA integrity while eliminating unwanted signal from hemoglobin transcripts, and supports longitudinal studies because dried samples are stable for months.

3TempO-Seq miRNA
CategoryTargeted Sequencing Assay
Description

A TempO-Seq-based assay for targeted, extraction-free measurement of miRNA expression across cell lines, FFPE tissues, plasma, and whole blood. The Human Whole miRNome panel includes 2,112 miRNA targets from miRBase v22.1 and supports custom panels for any species.

4TempO-LINC
CategorySingle-Cell Profiling Service
Description

A single-cell gene expression profiling service derived from TempO-Seq that combines templated oligo ligation with combinatorial split-pool barcoding for transcriptome-wide measurements at single-cell resolution. Customers receive a Fixation Kit, ship fixed samples, and BioSpyder processes and sequences them, delivering data 6-8 weeks after sample receipt in formats compatible with Seurat and Scanpy.

5TempO-SPan
CategoryPathogen Detection Assay
Description

A TempO-Seq variant for multiplexed detection of respiratory viruses, including SARS-CoV-2, Influenza A/B, and RSV. Supports up to 20 targets per panel, pools up to 6,144 samples per sequencing run, and includes automated calling software for patient reports. Custom detector oligo design enables additional pathogen targets.

6TempO-Seq Portal
CategoryCloud Analysis Software
Description

A cloud-based web portal for TempO-Seq data alignment, quality control, and differential expression analysis. Users upload FASTQ files for alignment against reference genomes and receive count tables, signal metrics per probe, PCA grouping, fold-change calculations, and correlation analysis through a GUI requiring no informaticist or installation.

7Bioinformatics Services
CategoryBioinformatics Services
Description

Managed bioinformatics consulting covering all phases of a TempO-Seq experiment, including custom probe design for transcript isoforms, genomic regions, and SNPs/INDELs; exploratory data analysis (PCA, heatmaps); differential gene expression analysis; machine learning-based classification for biomarker discovery delivered as standalone or cloud Web applications; pathway and gene ontology analysis; and single-cell analysis including clustering, t-SNE/UMAP, and differential expression between cell types.

8TempO-Seq Panels
CategoryPre-designed Assay Panels
Description

Pre-designed TempO-Seq panels covering Human Whole Transcriptome, Human PanCancer, Human S1500+ Surrogate, Mouse Whole Transcriptome, Rat Whole Transcriptome, Zebrafish S1500+, and EcoTox species (Daphnia magna, Chironomus dilutus, Pimephales promelas, Raphidocelis subcapitata). All panels support custom content additions or subtractions without impact on other targets in the signature.

9TempO-Seq Service Projects
CategorySequencing Service
Description

A fee-for-service offering in which BioSpyder processes customer samples using TempO-Seq and TempO-LINC, delivering FASTQ files, count tables, and service reports with typical turnaround of 4-6 weeks for TempO-Seq and 6-8 weeks for TempO-LINC. Customers ship samples and BioSpyder handles assay execution, sequencing, and primary data delivery.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NIH grants supporting TempO-Seq development from multiple institutes: National Human Genome Research Institute (NHGRI), National Institute of Environmental Health Sciences (NIEHS), and National Center for Advancing Translational Science (NCATS). Multiple completed grants including Alzheimer's disease research, single-cell profiling, genomic risk screening, and RNA epitranscriptomic modifications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

NHGRI funding for TempO-Seq Gene Expression Profiling Platform development and TempO-Seq for preserved tissues in toxicity and translational testing.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

NIEHS funding for TempO-Seq applications in toxicology research including multiplexed mRNA and miRNA profiling of single cells.

4National Center for Advancing Translational Science (NCATS)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NCATS funding for TempO-LINC high throughput single cell gene expression profiling assay development.

biospyder.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NCI contract (HHSN261201600059C) for cfNA TempO-Seq Assay development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

USDA funding for TempO-STAT Citrus Greening Infection Test (NIFA/USDA 2017-33610-26749).

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Global distributor for BioSpyder products. Based in Glasgow, Scotland. Handles distribution for Scotland and provides global coverage.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for Spain. Based in Valencia, Spain.

9LAS Co
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for South Korea. Based in Gimpo, Korea.

biospyder.com
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for Japan. Based in Osaka, Japan.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for Hong Kong. Based in New Territories, Hong Kong.

12Bang Trading 1992
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for Thailand. Based in Bangkok, Thailand.

biospyder.com
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for Singapore and Malaysia. Based in Singapore.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Takara Bio
TypeDirect peer
Description

A direct competitor in gene expression profiling via SMARTer stranded RNA-Seq kits and NGS targeted panels. Overlaps with BioSpyder's TempO-Seq miRNA, whole-transcriptome, and bulk targeted RNA workflows across academic and translational research buyers.

TypeDirect peer
Description

A direct competitor in targeted NGS panels (e.g., QIAseq targeted RNA panels) serving pharma toxicology and molecular diagnostics customers. Overlaps with BioSpyder on reagent kits, panel design, and bioinformatics services for targeted RNA expression.

TypeDirect peer
Description

A direct competitor in single-cell and targeted gene expression, particularly via Chromium and Visium platforms. TempO-LINC and BioSpyder's single-cell service offering compete with 10x's large-installed-base single-cell transcriptome workflows.

TypeBroad incumbent
Description

A broad incumbent offering Ion Torrent targeted NGS, Applied Biosystems TaqMan/qPCR panels, and full workflow solutions. Adjacent competitor across gene expression, transcriptomics, and clinical diagnostics markets where BioSpyder competes.

TypeBroad incumbent
Description

A broad incumbent offering ddSEQ single-cell expression, QX200 ddPCR, and various life science research tools. BioSpyder's CEO Joel McComb sits on Bio-Rad's board, signaling competitive overlap in droplet-based and targeted expression assays.

TypeDirect peer
Description

A direct niche competitor offering the EdgeSeq targeted sequencing platform for gene expression profiling from limited/FFPE samples without RNA extraction. EdgeSeq directly competes with TempO-Seq in the same extraction-free, no-library-prep targeted sequencing category.

TypeDirect peer
Description

A direct competitor in single-cell gene expression via the Hyperion / Imaging Mass Cytometry and original C1/Biomedical genomics platforms. Competes with TempO-LINC's high-throughput single-cell RNA profiling in toxicology and pharma research.

TypeDirect peer
Description

A direct competitor in targeted gene expression profiling with its nCounter platform and GeoMx digital spatial profiling. Both companies target toxicology, oncology, and pharma R&D buyers with multiplexed targeted RNA assays, and compete head-to-head for S1500+ adoption.

TypeBroad incumbent
Description

A broad incumbent dominating the sequencing market. BioSpyder's TempO-Seq reads out on Illumina sequencers and several founders (McComb, Yeakley) are ex-Illumina. Illumina's targeted RNA products and bundled reagent economics create pricing pressure on BioSpyder kits.

TypeBroad incumbent
Description

A broad incumbent in clinical diagnostics and life sciences tools with growing single-cell and targeted expression offerings. Adjacent competitor through its biosciences and diagnostic solutions businesses that overlap with BioSpyder's pathogen detection and molecular profiling workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioSpyder Technologies

Genomics Assay Productsbiospyder.com

BioSpyder Technologies develops and commercializes TempO-Seq, a proprietary targeted sequencing platform for high-throughput gene expression profiling that bypasses RNA extraction. The Carlsbad, California company sells assay kits, panels, and full-service sequencing to pharmaceutical, toxicology, oncology, and academic researchers globally.

What BioSpyder Technologies does

BioSpyder Technologies is a Carlsbad, California-based life sciences tools company founded in December 2011 by Joel McComb (CEO), Joanne Yeakley (VP R&D), and Bruce Seligmann (CSO) that develops and commercializes TempO-Seq (Templated Oligo-Sequencing), a proprietary targeted sequencing platform for gene expression profiling. The platform uses template-dependent detector oligo ligation chemistry that interrogates RNA directly without requiring RNA extraction, cDNA conversion, or pre-amplification, enabling analysis of cell lysates, FFPE tissue, frozen tissue, dried blood spots, and miRNA inputs on standard PCR instruments or microplate incubators. The platform can multiplex up to 6,144 samples per sequencing run with 99% single-base mismatch specificity and supports panels covering human, mouse, rat, zebrafish, and EcoTox species.

The company's product portfolio includes the core TempO-Seq assay, pre-designed whole-transcriptome and S1500+ surrogate panels, TempO-LINC (single-cell, launched 2025), TempO-Seq miRNA (2,112 targets), TempO-Seq Dried Blood Spot, TempO-SPan (pathogen detection including SARS-CoV-2/Influenza/RSV), and the upcoming TempO-SNP genotyping assay. BioSpyder also operates the TempO-Seq Portal cloud analysis module and offers managed bioinformatics services including probe design, differential expression analysis, and machine learning classification. Revenue is generated through quote-based kit and panel sales, full-service sample processing projects with 4–6 week turnaround, and bioinformatics consulting.

BioSpyder targets four primary customer segments: pharmaceutical and biotech companies conducting early compound screening and drug development safety assessment, toxicology and environmental science researchers (including regulatory chemical safety), oncology research groups pursuing biomarker discovery, and academic/government genomics labs. Commercial distribution is direct in the USA and through regional distributors covering Scotland, Spain, South Korea, Japan, Hong Kong, Thailand, Singapore, and Malaysia. The company is privately held by its three co-founders with no disclosed institutional investors; R&D has been substantially supported by competitive NIH grants from NHGRI, NIEHS, NCATS, NCI, and NIFA/USDA, and its technology is protected by a broad international patent estate.

BioSpyder Technologies firmographics

Firmographics
Name
BioSpyder Technologies
Legal name
BioSpyder, Inc.
Website
https://biospyder.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
BioSpyder Technologies develops and commercializes TempO-Seq, a proprietary targeted sequencing platform for high-throughput gene expression profiling that bypasses RNA extraction. The Carlsbad, California company sells assay kits, panels, and full-service sequencing to pharmaceutical, toxicology, oncology, and academic researchers globally.
Ownership category
akta.pro rank

BioSpyder Technologies industry classification

Industry
Product category
Genomics Assay Products
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Software Publishers (5132)
SIC
Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Gene expression profiling
  • Targeted sequencing assays
  • Single-cell transcriptomics
  • Molecular diagnostics tools
  • Bioinformatics analysis services

Where BioSpyder Technologies is headquartered

Location

Headquarters

HQ city
Carlsbad
HQ country
United States
HQ region
North America

Offices2 records

Markets served

BioSpyder Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. TempO-Seq Kits and Panels: Sale of assay kits including whole transcriptome panels, S1500+ surrogate panels, and custom panels for human, mouse, rat, zebrafish, and EcoTox species. Customers can purchase panels directly and run assays in their own labs.
  2. Service Projects: BioSpyder processes customer samples using TempO-Seq and TempO-LINC platforms. Service projects typically have 4-6 week turnaround. Deliverables include FASTQ files, count tables, and service reports.
  3. Bioinformatics Services: Additional data analysis support including probe design, exploratory data analysis, differential gene expression analysis, machine learning classification, pathway analysis, and single-cell analysis.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goKits and panels - quote-based pricing

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

BioSpyder Technologies product offering

Product offering

Core offering

BioSpyder develops and sells the TempO-Seq (Templated Oligo-Sequencing) targeted sequencing platform for gene expression profiling, offering assay kits and pre-designed panels (human, mouse, rat, zebrafish, EcoTox species) that customers run in their own labs, as well as fee-for-service projects (4–8 week turnaround) where BioSpyder processes customer samples and delivers FASTQ files, count tables, and analysis reports. The proprietary chemistry eliminates RNA extraction, cDNA conversion, and pre-amplification, supports multiplexing of up to 6,144 samples per run, and is complemented by the cloud-based TempO-Seq Portal and managed bioinformatics services.

Product overview

BioSpyder Technologies offers the TempO-Seq (Templated Oligo-Sequencing) platform as its core product — a targeted sequencing system for gene expression profiling that avoids RNA extraction, cDNA conversion, or pre-amplification through proprietary detector oligo ligation chemistry. The platform comprises multiple specialized sub-products: TempO-Seq (core targeted sequencing assay accepting diverse inputs), TempO-Seq Dried Blood Spot (blood-based transcriptomics), TempO-Seq miRNA (microRNA profiling), TempO-LINC (single-cell expression profiling service), TempO-SNP (SNP detection, upcoming), and TempO-SPan (pathogen/respiratory virus detection). These are complemented by the TempO-Seq Portal cloud analysis module and managed Bioinformatics Services for custom probe design, differential expression, machine learning classification, pathway analysis, and single-cell analysis. Pre-designed panels cover human, mouse, rat, zebrafish transcriptomes and EcoTox species. The platform is validated across applications in toxicology, oncology, pharma, computational biology, and agriculture.

Differentiator

Problem solved

Functional benefit

Brands

  • TempO-Seq: Proprietary targeted sequencing platform for gene expression profiling using templated oligo detection chemistry, capable of analyzing hundreds to thousands of genes in high throughput.
  • TempO-LINC
  • TempO-SPan
  • TempO-SNP
  • TempO-Seq Portal

Products and services

  • TempO-Seq TempO-Seq (Templated Oligo-Sequencing) is a targeted sequencing assay for gene expression profiling that monitors hundreds to thousands of genes in high throughput without RNA extraction, cDNA conversion, or pre-amplification. It uses proprietary detector oligo ligation chemistry, accepts diverse input types (cell lysates, FFPE tissue, frozen tissue, dried blood spots, miRNA), and enables pooling of up to 6,144 samples per run on standard PCR instruments or microplate incubators.
  • TempO-Seq Dried Blood Spot A TempO-Seq variant that enables whole transcriptome profiling from dried whole blood or buffy coat samples on filter paper, collected by finger prick or venipuncture. Uses modified chemistry that maintains RNA integrity while eliminating unwanted signal from hemoglobin transcripts, and supports longitudinal studies because dried samples are stable for months.
  • TempO-Seq miRNA A TempO-Seq-based assay for targeted, extraction-free measurement of miRNA expression across cell lines, FFPE tissues, plasma, and whole blood. The Human Whole miRNome panel includes 2,112 miRNA targets from miRBase v22.1 and supports custom panels for any species.
  • TempO-LINC A single-cell gene expression profiling service derived from TempO-Seq that combines templated oligo ligation with combinatorial split-pool barcoding for transcriptome-wide measurements at single-cell resolution. Customers receive a Fixation Kit, ship fixed samples, and BioSpyder processes and sequences them, delivering data 6-8 weeks after sample receipt in formats compatible with Seurat and Scanpy.
  • TempO-SPan A TempO-Seq variant for multiplexed detection of respiratory viruses, including SARS-CoV-2, Influenza A/B, and RSV. Supports up to 20 targets per panel, pools up to 6,144 samples per sequencing run, and includes automated calling software for patient reports. Custom detector oligo design enables additional pathogen targets.
  • TempO-Seq Portal A cloud-based web portal for TempO-Seq data alignment, quality control, and differential expression analysis. Users upload FASTQ files for alignment against reference genomes and receive count tables, signal metrics per probe, PCA grouping, fold-change calculations, and correlation analysis through a GUI requiring no informaticist or installation.
  • Bioinformatics Services Managed bioinformatics consulting covering all phases of a TempO-Seq experiment, including custom probe design for transcript isoforms, genomic regions, and SNPs/INDELs; exploratory data analysis (PCA, heatmaps); differential gene expression analysis; machine learning-based classification for biomarker discovery delivered as standalone or cloud Web applications; pathway and gene ontology analysis; and single-cell analysis including clustering, t-SNE/UMAP, and differential expression between cell types.
  • TempO-Seq Panels Pre-designed TempO-Seq panels covering Human Whole Transcriptome, Human PanCancer, Human S1500+ Surrogate, Mouse Whole Transcriptome, Rat Whole Transcriptome, Zebrafish S1500+, and EcoTox species (Daphnia magna, Chironomus dilutus, Pimephales promelas, Raphidocelis subcapitata). All panels support custom content additions or subtractions without impact on other targets in the signature.
  • TempO-Seq Service Projects A fee-for-service offering in which BioSpyder processes customer samples using TempO-Seq and TempO-LINC, delivering FASTQ files, count tables, and service reports with typical turnaround of 4-6 weeks for TempO-Seq and 6-8 weeks for TempO-LINC. Customers ship samples and BioSpyder handles assay execution, sequencing, and primary data delivery.

Quantifiable outcome

  • Up to 6,144 samples multiplexed in single sequencing run
  • +4 more outcomes

Companies that use BioSpyder Technologies

Customer profile

Segments4 records

Ideal customer profiles4 records

BioSpyder Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature6 records

BioSpyder Technologies partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and regional.

  • National Institutes of Health (NIH)coreStrategic or Co-development PartnerNIH grants supporting TempO-Seq development from multiple institutes: National Human Genome Research Institute (NHGRI), National Institute of Environmental Health Sciences (NIEHS), and National Center for Advancing Translational Science (NCATS). Multiple completed grants including Alzheimer's disease research, single-cell profiling, genomic risk screening, and RNA epitranscriptomic modifications.
  • National Human Genome Research Institute (NHGRI)coreStrategic or Co-development PartnerNHGRI funding for TempO-Seq Gene Expression Profiling Platform development and TempO-Seq for preserved tissues in toxicity and translational testing.
  • National Institute of Environmental Health Sciences (NIEHS)coreStrategic or Co-development PartnerNIEHS funding for TempO-Seq applications in toxicology research including multiplexed mRNA and miRNA profiling of single cells.
  • National Center for Advancing Translational Science (NCATS)coreStrategic or Co-development PartnerNCATS funding for TempO-LINC high throughput single cell gene expression profiling assay development.
  • National Cancer Institute (NCI)coreStrategic or Co-development PartnerNCI contract (HHSN261201600059C) for cfNA TempO-Seq Assay development.
  • NIFA/USDAcoreStrategic or Co-development PartnerUSDA funding for TempO-STAT Citrus Greening Infection Test (NIFA/USDA 2017-33610-26749).
  • BioClavis Ltd.coreChannel Partner/ Reseller/ DistributorGlobal distributor for BioSpyder products. Based in Glasgow, Scotland. Handles distribution for Scotland and provides global coverage.
  • Durviz S.LregionalChannel Partner/ Reseller/ DistributorRegional distributor for Spain. Based in Valencia, Spain.
  • LAS CoregionalChannel Partner/ Reseller/ DistributorRegional distributor for South Korea. Based in Gimpo, Korea.
  • AS-ONEregionalChannel Partner/ Reseller/ DistributorRegional distributor for Japan. Based in Osaka, Japan.
  • ATCGregionalChannel Partner/ Reseller/ DistributorRegional distributor for Hong Kong. Based in New Territories, Hong Kong.
  • Bang Trading 1992regionalChannel Partner/ Reseller/ DistributorRegional distributor for Thailand. Based in Bangkok, Thailand.
  • Atlantis BioscienceregionalChannel Partner/ Reseller/ DistributorRegional distributor for Singapore and Malaysia. Based in Singapore.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

BioSpyder Technologies competitors and assessment

Company assessment

Direct peers

  • Takara Bio: A direct competitor in gene expression profiling via SMARTer stranded RNA-Seq kits and NGS targeted panels. Overlaps with BioSpyder's TempO-Seq miRNA, whole-transcriptome, and bulk targeted RNA workflows across academic and translational research buyers.
  • QIAGEN: A direct competitor in targeted NGS panels (e.g., QIAseq targeted RNA panels) serving pharma toxicology and molecular diagnostics customers. Overlaps with BioSpyder on reagent kits, panel design, and bioinformatics services for targeted RNA expression.
  • 10x Genomics: A direct competitor in single-cell and targeted gene expression, particularly via Chromium and Visium platforms. TempO-LINC and BioSpyder's single-cell service offering compete with 10x's large-installed-base single-cell transcriptome workflows.
  • HTG Molecular Diagnostics: A direct niche competitor offering the EdgeSeq targeted sequencing platform for gene expression profiling from limited/FFPE samples without RNA extraction. EdgeSeq directly competes with TempO-Seq in the same extraction-free, no-library-prep targeted sequencing category.
  • Standard BioTools (formerly Fluidigm): A direct competitor in single-cell gene expression via the Hyperion / Imaging Mass Cytometry and original C1/Biomedical genomics platforms. Competes with TempO-LINC's high-throughput single-cell RNA profiling in toxicology and pharma research.
  • NanoString Technologies: A direct competitor in targeted gene expression profiling with its nCounter platform and GeoMx digital spatial profiling. Both companies target toxicology, oncology, and pharma R&D buyers with multiplexed targeted RNA assays, and compete head-to-head for S1500+ adoption.

Broad incumbents

  • Thermo Fisher Scientific: A broad incumbent offering Ion Torrent targeted NGS, Applied Biosystems TaqMan/qPCR panels, and full workflow solutions. Adjacent competitor across gene expression, transcriptomics, and clinical diagnostics markets where BioSpyder competes.
  • Bio-Rad Laboratories: A broad incumbent offering ddSEQ single-cell expression, QX200 ddPCR, and various life science research tools. BioSpyder's CEO Joel McComb sits on Bio-Rad's board, signaling competitive overlap in droplet-based and targeted expression assays.
  • Illumina: A broad incumbent dominating the sequencing market. BioSpyder's TempO-Seq reads out on Illumina sequencers and several founders (McComb, Yeakley) are ex-Illumina. Illumina's targeted RNA products and bundled reagent economics create pricing pressure on BioSpyder kits.
  • Becton, Dickinson and Company (BD): A broad incumbent in clinical diagnostics and life sciences tools with growing single-cell and targeted expression offerings. Adjacent competitor through its biosciences and diagnostic solutions businesses that overlap with BioSpyder's pathogen detection and molecular profiling workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

BioSpyder Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioSpyder Technologies leadership team

Management profile

Number of profiles

Profiles4 records

BioSpyder Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioSpyder Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioSpyder Technologies

What does BioSpyder Technologies do?

BioSpyder develops and sells the TempO-Seq (Templated Oligo-Sequencing) targeted sequencing platform for gene expression profiling, offering assay kits and pre-designed panels (human, mouse, rat, zebrafish, EcoTox species) that customers run in their own labs, as well as fee-for-service projects (4–8 week turnaround) where BioSpyder processes customer samples and delivers FASTQ files, count tables, and analysis reports. The proprietary chemistry eliminates RNA extraction, cDNA conversion, and pre-amplification, supports multiplexing of up to 6,144 samples per run, and is complemented by the cloud-based TempO-Seq Portal and managed bioinformatics services.

Is BioSpyder Technologies a public or private company?

BioSpyder Technologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BioSpyder Technologies founded?

BioSpyder Technologies was founded in 2011. It employs 11 to 50 people.

Where is BioSpyder Technologies based?

BioSpyder Technologies is headquartered in Carlsbad, United States, in the North America region.

How does BioSpyder Technologies make money?

Three revenue lines are on record. TempO-Seq Kits and Panels are the primary driver. The others are service Projects and bioinformatics Services.

Who are BioSpyder Technologies's main competitors?

Direct peers on record are Takara Bio, QIAGEN, 10x Genomics, HTG Molecular Diagnostics, Standard BioTools (formerly Fluidigm) and NanoString Technologies. Broad incumbents are Thermo Fisher Scientific, Bio-Rad Laboratories, Illumina and Becton, Dickinson and Company (BD).

Does BioSpyder Technologies have an API?

No public API is recorded for BioSpyder Technologies.

What industry is BioSpyder Technologies in?

BioSpyder Technologies's product category is Genomics Assay Products. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAGANAE, Transcriptomics & Gene Expression Profiling Services. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales